onctalk 2020, connecting patients to the experts
Published 3 years ago • 126 plays • Length 2:35:24Download video MP4
Download video MP3
Similar videos
-
3:41
cellular therapies in multiple myeloma - blood cancer onctalk
-
7:39
car t-cell versus bispecific therapies: how oncologists determine treatment - blood cancer onctalk
-
26:56
gracecast-085_lung-cancer_alk inhibition: who to screen and options for alk-positive patients
-
2:22:00
onctalk 2022 -- on demand full video
-
10:02
gracecast-137_ca-101-_dr. ramalingam: q and a session on clinical trials in oncology
-
2:06
patient role in bispecific antibody treatment - blood cancer onctalk 2023
-
6:16
treatment options for multiple myeloma - blood cancer onctalk
-
1:44
extended interval dosing for pembrolizumab - lung cancer onctalk 2022
-
2:02
onctalk 2021 - immunotherapy in pdl1 and egfr
-
4:12
trials for patients with actionable mutations, & the importance of quality of life - onctalk 2022
-
2:26
risk adaptive management for high risk multiple myeloma - blood cancer onctalk
-
3:40
should cellular therapies be moved to first line treatment? - blood cancer onctalk
-
2:25
maintenance treatment in multiple myeloma - blood cancer onctalk
-
4:15
treatment timing for multiple myeloma - blood cancer onctalk
-
1:48
preoperative or postoperative immunotherapy? - lung cancer onctalk 2022
-
6:56
what is multiple myeloma? - 2024 blood cancer onctalk
-
10:43
gracecast-007_lung-cancer_optimal treatment of unresectable locally advanced nsclc
-
1:57
keynote 091: adjuvant pembrolizumab - onctalk lung 2023
-
6:21
grace & cco - immunotherapy for advanced nsclc: discussing goals &treatments with your providers